NDA 202429 · Hoffmann La Roche
Zelboraf
Vemurafenib · Oral · Kinase Inhibitor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Aug 17, 2011
Approved uses
5
Original approval plus efficacy supplements
Registered trials
156
14 Phase 3, 15 recruiting
FAERS reports
11,990
8,963 serious, 2,076 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 28, 2026.
ZELBORAF ® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) ZELBORAF ® is indicated for the treatment of patients with Erdheim- Chester Disease with BRAF V600 mutation. ( 1.2 , 2.1 ) Limitation of Use: ZELBORAF is not indicated for treatment of patients with wild-type BRAF melanoma ( 2.1 , 5.2 ) 1.1 Unresectable or Metastatic Melanoma ZELBORAF ® is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. Limitation of Use: ZELBORAF is not indicated for treatment of patients with wild-type BRAF melanoma [see Warnings and Precautions (5.2) ] . 1.2 Erdheim-Chester Disease ZELBORAF ® is indicated for the treatment of patients with Erdheim-Chester Disease (ECD) with BRAF V600 mutation.
Mechanism: Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of BRAF serine- threonine kinase, including BRAF V600E. Vemurafenib also inhibits other kinases in vitro such as CRAF, ARAF, wild-type BRAF, SRMS, ACK1, MAP4K5, and FGR at similar concentrations. Some mutations in the BRAF gene including V600E result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation. Vemurafenib has anti-tumor effects in cellular and animal models of melanomas with mutated BRAF...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 6, 2017 Supplement 16 · Efficacy · priority review Breakthrough therapyOrphanLabelMedication GuideLetter
- Sep 13, 2017 Supplement 14 · Efficacy OrphanLetter
- Aug 31, 2016 Supplement 9 · Efficacy LabelLetter
- Mar 19, 2014 Supplement 4 · Efficacy OrphanLabelLetter
- Aug 17, 2011 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewSummary Review
1 products under this application
- ZELBORAF · VEMURAFENIB 240MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vemurafenib" as an intervention, any sponsor and status, largest first.
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
- A Study of Vemurafenib in Participants With Metastatic MelanomaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01307397 · 3,219 participants · Start Mar 1, 2011 · Primary completion Feb 24, 2016
Drug: Vemurafenib · For: Malignant Melanoma
Sites: Tirana, Albania; Buenos Aires, Argentina; North Sydney, Australia · 280 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
National Cancer Institute (NCI)NIH
NCT03155620 · 1,377 participants · Start Jul 31, 2017 · Primary completion Mar 31, 2025
Drug: Ensartinib; Erdafitinib and 11 more · For: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma and 42 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Mesa, Arizona · 172 sites in all
- A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02291289 · 1,044 participants · Start Apr 17, 2015 · Primary completion May 31, 2019
Drug: Cetuximab; FOLFOX induction regimen and 9 more · For: Colorectal Cancer
Sites: Buenos Aires, Argentina; La Rioja, Argentina; Viedma Rio Negro, Argentina · 154 sites in all
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03768063 · 1,000 participants (planned) · Start Feb 28, 2019 · Primary completion Jul 5, 2028
Drug: Atezolizumab; Bevacizumab and 14 more · For: Cancer
Sites: Aurora, Colorado; Trumbull, Connecticut; Boston, Massachusetts · 80 sites in all
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03178552 · 1,000 participants (planned) · Start Sep 22, 2017 · Primary completion Jun 30, 2027
Drug: Alectinib; Atezolizumab and 10 more · For: Non-Small Cell Lung Cancer
Sites: Sacramento, California; Denver, Colorado; Fort Myers, Florida · 161 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- rash1,554
- death1,065
- arthralgia1,043
- fatigue1,039
- off label use875
- diarrhoea828
- nausea812
- disease progression768
- pyrexia744
- alopecia563
- decreased appetite534
- vomiting475
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2011 | 167 |
| 2012 | 1,408 |
| 2013 | 1,462 |
| 2014 | 849 |
| 2015 | 691 |
| 2016 | 2,670 |
| 2017 | 799 |
| 2018 | 842 |
| 2019 | 668 |
| 2020 | 579 |
| 2021 | 453 |
| 2022 | 375 |
| 2023 | 241 |
| 2024 | 467 |
| 2025 | 199 |
| 2026 | 119 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zelboraf (Vemurafenib)
2024 spending
$13.4M
Beneficiaries
332
1,787 claims
Per beneficiary
$40,479
$50.79 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $12,356,693 |
| 2021 | $13,717,070 |
| 2022 | $13,184,077 |
| 2023 | $12,983,918 |
| 2024 | $13,439,109 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
Brastianos PK, Twohy E, Geyer S, et al. · N Engl J Med 2023 · Clinical Trial, Phase II, Research Support, U.S. Gov't, P.H.S.
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB, Hauschild A, Robert C, et al. · N Engl J Med 2011 · Clinical Trial, Phase III, Comparative Study
- Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C, Karaszewska B, Schachter J, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Comparative Study
- COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Schadendorf D, Dummer R, Flaherty KT, et al. · Eur J Cancer 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
Diamond EL, Subbiah V, Lockhart AC, et al. · JAMA Oncol 2018 · Clinical Trial, Phase II, Multicenter Study
- Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).
Kopetz S, Guthrie KA, Morris VK, et al. · J Clin Oncol 2021 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.